At the City of Hope site, 4/4 patients (with data) had clinical and/or biomarker responses, i.e. declines in CEA, CA19-9, and/or ctDNA, despite refractory liver-metastatic disease. Serial kinetics showed an increase in PD-L1 on CTCs and CAMLs after 1 week on treatment, while the number of CAMLs and CTCs lowered in responders.
PD-L1 increase in CAMLs or CTCs* 60% (n=3/5)
https://www.abstractsonline.com/pp8/#!/21436/...ation/9510